Collectively, the data revealed that NLRP3 knockdown and the inactivation of NLRP3 inflammasome might weaken the malignant phenotype of ovarian cancer with DDP resistance and regulate the chemoresistance of ovarian cancer cells to DDP-based therapy. The gene discussed is NLRP3; the disease is ovarian cancer.